Published in J Biomed Mater Res on November 01, 1987
HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev (2009) 2.13
Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed (2007) 2.12
In situ-gelling, erodible N-isopropylacrylamide copolymers. Macromol Biosci (2005) 1.44
Polymer-drug conjugates: origins, progress to date and future directions. Adv Drug Deliv Rev (2012) 1.28
Drug targeting with nano-sized carrier systems. J Artif Organs (2005) 1.17
ATRP in the design of functional materials for biomedical applications. Prog Polym Sci (2011) 1.15
Backbone degradable multiblock N-(2-hydroxypropyl)methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction. Biomacromolecules (2010) 1.08
Development of macromolecular prodrug for rheumatoid arthritis. Adv Drug Deliv Rev (2012) 1.07
Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. Nanomedicine (Lond) (2008) 1.04
Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol Pharm (2006) 1.03
Design, synthesis, and biological evaluation of a robust, biodegradable dendrimer. Bioconjug Chem (2010) 1.00
Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel. J Control Release (2012) 0.99
In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat Biotechnol (2015) 0.98
Polysaccharide-modified synthetic polymeric biomaterials. Biopolymers (2010) 0.94
Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates. Proc Natl Acad Sci U S A (2014) 0.94
Biological rationale for the design of polymeric anti-cancer nanomedicines. J Drug Target (2012) 0.93
Synthesis and characterization of a new class of cationic protein polymers for multivalent display and biomaterial applications. Biomacromolecules (2009) 0.93
Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A''-DTPA) conjugates show increased kidney accumulation. J Control Release (2008) 0.93
Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells. Mol Pharm (2008) 0.92
Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model. Mol Pharm (2010) 0.92
Noninvasive monitoring of HPMA copolymer-RGDfK conjugates by magnetic resonance imaging. Pharm Res (2009) 0.91
Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery. Mol Pharm (2009) 0.88
Macromolecular therapeutics. J Control Release (2014) 0.87
Intracellular trafficking and subcellular distribution of a large array of HPMA copolymers. Biomacromolecules (2009) 0.87
Semitelechelic HPMA copolymers functionalized with triphenylphosphonium as drug carriers for membrane transduction and mitochondrial localization. Biomacromolecules (2006) 0.86
Beyond oncology--application of HPMA copolymers in non-cancerous diseases. Adv Drug Deliv Rev (2009) 0.86
Synthesis of long-circulating, backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy. Macromol Biosci (2013) 0.86
177Lu-labeled HPMA copolymers utilizing cathepsin B and S cleavable linkers: synthesis, characterization and preliminary in vivo investigation in a pancreatic cancer model. Nucl Med Biol (2013) 0.85
Cellular uptake of functional nanogels prepared by inverse miniemulsion ATRP with encapsulated proteins, carbohydrates, and gold nanoparticles. Biomacromolecules (2009) 0.85
Synergistic enhancement of cancer therapy using a combination of heat shock protein targeted HPMA copolymer-drug conjugates and gold nanorod induced hyperthermia. J Control Release (2013) 0.85
Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br J Cancer (1988) 0.83
Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats. Biomaterials (2013) 0.82
The cytoplasmic escape and nuclear accumulation of endocytosed and microinjected HPMA copolymers and a basic kinetic study in Hep G2 cells. AAPS PharmSci (2001) 0.82
Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain. MAbs (2013) 0.82
Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs. Int J Pharm (2007) 0.81
Diverse Applications of Nanomedicine. ACS Nano (2017) 0.80
The cytotoxic effects of lipidic formulated gold porphyrin nanoparticles for the treatment of neuroblastoma. Nanotechnol Sci Appl (2010) 0.78
HPMA copolymer-doxorubicin-gadolinium conjugates: synthesis, characterization, and in vitro evaluation. Macromol Biosci (2008) 0.78
Tailoring polymersome bilayer permeability improves enhanced permeability and retention effect for bioimaging. ACS Appl Mater Interfaces (2014) 0.78
The influence of linker length on the properties of cathepsin S cleavable (177)Lu-labeled HPMA copolymers for pancreatic cancer imaging. Biomaterials (2014) 0.77
Biopolymer-based delivery systems for advanced imaging and skeletal tissue-specific therapeutics. J Bone Miner Metab (2005) 0.77
Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells. Eur J Pharm Biopharm (2013) 0.77
Design of smart HPMA copolymer-based nanomedicines. J Control Release (2015) 0.76
N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice. Br J Cancer (1991) 0.76
POLYMERIC BIOMATERIALS AND NANOMEDICINES. J Drug Deliv Sci Technol (2015) 0.76
Low-molecular-weight polymer-drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations. Nanomedicine (Lond) (2016) 0.75
Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J Biol Chem (1987) 4.48
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release (2000) 3.07
General practice computing in Scotland. BMJ (1990) 2.06
Programmed cell death in the unicellular protozoan parasite Leishmania. Cell Death Differ (2002) 2.05
Heat shock-induced translational alterations in HeLa cells. Initiation factor modifications and the inhibition of translation. J Biol Chem (1984) 1.99
Identification and quantitation of levels of protein synthesis initiation factors in crude HeLa cell lysates by two-dimensional polyacrylamide gel electrophoresis. J Biol Chem (1983) 1.97
Regulation of initiation factors during translational repression caused by serum depletion. Covalent modification. J Biol Chem (1985) 1.83
Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains. Nature (1999) 1.78
Heterogeneous nuclear ribonucleoprotein A1 binds to the transcription-regulatory region of mouse hepatitis virus RNA. Proc Natl Acad Sci U S A (1997) 1.70
Disability, distress and unemployment in neurology outpatients with symptoms 'unexplained by organic disease'. J Neurol Neurosurg Psychiatry (2011) 1.69
Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res (1998) 1.68
Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs (1999) 1.67
A new class of fusion-associated small transmembrane (FAST) proteins encoded by the non-enveloped fusogenic reoviruses. EMBO J (2000) 1.66
Seizure risk from cavernous or arteriovenous malformations: prospective population-based study. Neurology (2011) 1.62
Preferential utilization of phosphorylated 40-S ribosomal subunits during initiation complex formation. Eur J Biochem (1982) 1.62
Mechanism of interferon action. Increased phosphorylation of protein synthesis initiation factor eIF-2 alpha in interferon-treated, reovirus-infected mouse L929 fibroblasts in vitro and in vivo. J Biol Chem (1984) 1.61
Psychopathology in people with epilepsy and intellectual disability; an investigation of potential explanatory variables. J Neurol Neurosurg Psychiatry (2003) 1.53
The safety of antiepileptic drug withdrawal in patients with non-epileptic seizures. J Neurol Neurosurg Psychiatry (2005) 1.52
The nucleotide sequence of infectious pancreatic necrosis virus (IPNV) dsRNA segment A reveals one large ORF encoding a precursor polyprotein. Nucleic Acids Res (1986) 1.47
Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Release (1998) 1.45
Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med (1989) 1.41
Comparison of bimanual examination with ultrasound examination before hysterectomy for uterine leiomyoma. Obstet Gynecol (1998) 1.41
Many universities do teach professionalism. Br J Nurs (2002) 1.39
Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer (2000) 1.34
HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release (1998) 1.33
Clinical classification criteria for knee osteoarthritis: performance in the general population and primary care. Ann Rheum Dis (2006) 1.32
Prevalence of evidence of prior myocardial infarction, hypertension, diabetes and obesity in three neighboring communities in Pennsylvania. Am J Med Sci (1967) 1.31
Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice. Eur J Cancer (2001) 1.30
Simple methods for assessing haplotype-environment interactions in case-only and case-control studies. Genet Epidemiol (2007) 1.29
Soluble biomedical polymers. Polim Med (1977) 1.28
Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer (1995) 1.26
Biochemical and biophysical characterization of the reovirus cell attachment protein sigma 1: evidence that it is a homotrimer. Virology (1991) 1.25
Protein-resistant surfaces prepared by PEO-containing block copolymer surfactants. J Biomed Mater Res (1989) 1.24
Double-stranded RNA-dependent protein kinase and 2-5A system are both activated in interferon-treated, encephalomyocarditis virus-infected HeLa cells. J Virol (1985) 1.24
Rapid alterations in initiation rate and recruitment of inactive RNA are temporally correlated with S6 phosphorylation. Eur J Biochem (1982) 1.23
Osteoclast cytosolic calcium, regulated by voltage-gated calcium channels and extracellular calcium, controls podosome assembly and bone resorption. J Cell Biol (1990) 1.21
New ways of initiating translation in eukaryotes. Mol Cell Biol (2001) 1.20
Polyelectrolyte vectors for gene delivery: influence of cationic polymer on biophysical properties of complexes formed with DNA. Bioconjug Chem (2000) 1.20
Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation. J Control Release (2000) 1.19
Targeted melting and binding of a DNA regulatory element by a transactivator of c-myc. J Biol Chem (1995) 1.19
Congenital talipes equinovarus: a review of current management. J Bone Joint Surg Br (2007) 1.18
The cell attachment proteins of type 1 and type 3 reovirus are differentially susceptible to trypsin and chymotrypsin. Virology (1989) 1.16
Protein synthesis eukaryotic initiation factors 4A and 4B are not altered by poliovirus infection of HeLa cells. J Biol Chem (1983) 1.13
Guided self-help for functional (psychogenic) symptoms: a randomized controlled efficacy trial. Neurology (2011) 1.12
Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharm Res (2000) 1.12
Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J Control Release (1999) 1.12
The contribution of selected non-articular conditions to knee pain severity and associated disability in older adults. Osteoarthritis Cartilage (2008) 1.11
Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int J Pharm (1999) 1.10
Pinocytosis in the rat visceral yolk sac. Effects of temperature, metabolic inhibitors and some other modifiers. Biochim Biophys Acta (1978) 1.09
Who is referred to neurology clinics?--the diagnoses made in 3781 new patients. Clin Neurol Neurosurg (2010) 1.08
Surface properties of copolymers of alkyl methacrylates with methoxy (polyethylene oxide) methacrylates and their application as protein-resistant coatings. Biomaterials (1990) 1.07
Symptoms 'unexplained by organic disease' in 1144 new neurology out-patients: how often does the diagnosis change at follow-up? Brain (2009) 1.06
Site-directed mutagenesis of the C-terminal portion of reovirus protein sigma 1: evidence for a conformation-dependent receptor binding domain. Virology (1992) 1.05
Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. Biochim Biophys Acta (1986) 1.04
Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers. Biochim Biophys Acta (1984) 1.03
Membrane economics in endocytic systems. J Theor Biol (1977) 1.03
Rubella virus E2 signal peptide is required for perinuclear localization of capsid protein and virus assembly. J Virol (2001) 1.02
Expression of a mutant form of Leishmania donovani centrin reduces the growth of the parasite. J Biol Chem (2001) 1.02
Predicting the course of functional limitation among older adults with knee pain: do local signs, symptoms and radiographs add anything to general indicators? Ann Rheum Dis (2008) 1.02
Phosphorylation of ribosomal protein S6. Relationship to protein synthesis in HeLa cells. Eur J Biochem (1981) 1.01
Novel pH-sensitive hydrogels with adjustable swelling kinetics. Biomaterials (1998) 1.00
Hybrid hydrogels cross-linked by genetically engineered coiled-coil block proteins. Biomacromolecules (2001) 1.00
Sleep disturbances in men with asymptomatic human immunodeficiency (HIV) infection. Sleep (1992) 1.00
Entamoeba histolytica interactions with polarized human intestinal Caco-2 epithelial cells. Infect Immun (1994) 1.00
Decreased binding to proteins and cells of polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer and retargeting through attachment of transferrin. J Biol Chem (2000) 0.99
Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia. Arch Dis Child (2010) 0.99
Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm Res (1999) 0.99
Long-term experience with poly(glycol monomethacrylate) gel in plastic operations of the nose. J Biomed Mater Res (1975) 0.98
An assessment of computing activity by GPASS users in Scottish general practice. Health Bull (Edinb) (1991) 0.98
Hepatitis C infection in two urban hemodialysis units. Kidney Int (1990) 0.98
Diagnostic findings in the 1992 epornitic of neurotropic velogenic Newcastle disease in double-crested cormorants from the upper midwestern United States. Avian Dis (1997) 0.98
The pharmacokinetics of polymer-bound adriamycin. Biochem Pharmacol (1990) 0.98
Controlled biodegradability of polymers--a key to drug delivery systems. Biomaterials (1984) 0.97
Polymerizable Fab' antibody fragments for targeting of anticancer drugs. Nat Biotechnol (1999) 0.97
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer (2005) 0.97
Autoantigens interact with cis-acting elements of rubella virus RNA. J Virol (1996) 0.97
Detecting seizure origin using basic, multiscale population dynamic measures: preliminary findings. Epilepsy Behav (2008) 0.96
The impact of the addition of an acupuncture treatment program to an existing metro-Dade County outpatient substance abuse treatment facility. J Addict Dis (1994) 0.95
Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats. Pharm Res (2008) 0.95
How many proteins are there in a typical mammalian cell? Clin Chem (1982) 0.95
Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells. Bioconjug Chem (2001) 0.95
The N-terminal heptad repeat region of reovirus cell attachment protein sigma 1 is responsible for sigma 1 oligomer stability and possesses intrinsic oligomerization function. Virology (1991) 0.95
Electrical conductivities of the freshly excised cerebral cortex in epilepsy surgery patients; correlation with pathology, seizure duration, and diffusion tensor imaging. Brain Topogr (2006) 0.94
Regulation of initiation factors during translational repression caused by serum depletion. Abundance, synthesis, and turnover rates. J Biol Chem (1985) 0.94
Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells. Eur J Cancer (2004) 0.94
HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J Drug Target (1996) 0.94